trending Market Intelligence /marketintelligence/en/news-insights/trending/CEWtgZ8MlmEG3-9A9jOJAg2 content esgSubNav
In This List

Oxford Immunotec, Qiagen settle patent infringement lawsuit

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Oxford Immunotec, Qiagen settle patent infringement lawsuit

Oxford Immunotec Global PLC and Qiagen NV settled a lawsuit regarding alleged patent infringement of Qiagen products.

The suit, filed in U.S. District Court for the District of Massachusetts in Boston, covered the Dutch company's QuantiFeron-TB gold and QuantiFeron-TB Gold Plus products.

U.K.-based Oxford granted Qiagen a royalty-free, nonexclusive license that extends to all current and future customers of the two Qiagen products in exchange for a one-time lump sum of $27.5 million.

Under the settlement, all pending claims between Oxford and Qiagen and the co-defendants were resolved. None of the parties admitted to any wrongdoing.

QuantiFeron-TB Gold is a diagnostic aid that detects infection caused by Mycobacterium tuberculosis, a type of bacteria that causes tuberculosis.